Both analyses were presented virtually after the Heart Failure Society of America ... patients with known diabetes) and STEP-HFpEF DM (including those with type 2 diabetes). In both trials, ...

Among the benefits of semaglutide, the GLP-1 receptor agonist may protect against heart failure events in patients with type 2 diabetes and CKD.

Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

In both trials, Wegovy demonstrated greater reductions in heart failure-related symptoms ... The primary objective of STEP HFpEF and STEP HFpEF-DM trials was to investigate the effects of subcutaneous ...

Semaglutide significantly reduces cardiovascular events and adverse effects in overweight and obese patients. The study ...

The positive opinion is based on the results from the STEP HFpEF and STEP HFpEF-DM trials. In both trials, Wegovy demonstrated greater reductions in heart failure-related symptoms, improvements in ...

The active ingredient in Mounjaro and Zepbound may reduce the risk of hospitalization and death from heart failure ... with HFpEF in comparison to a placebo. “Both drugs [semaglutide and ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure ... Novo Nordisk's STEP-HFpEF study of semaglutide is that ...

The label update incorporates data showing that Wegovy, when added to standard of care, can reduce heart failure-related symptoms ... based on results from the STEP HFpEF and STEP HFpEF-DM trials ...

Lilly Says Weight Loss Drug Cuts Heart Failure Risk by 38% in Trial ... Obesity Two new analyses of the STEP-HFpEF trials show that semaglutide led to more weight loss in women than in men and ...